Avacta Group Plc (AVCT) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Evactor Group CLC investor presentation. Throughout the recorded presentation, investors will be in the scenario mode. Questions are encouraged and can be submitted at any time by the Q&A tab situated in the right corner of your screen. Simply type in your questions and press send. Due to the high attendance on today's call, the company may not be in a position to answer every question it receives in the meeting itself. However, the company can view all the questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand over to CEO Christina Coughlin. Good morning. Good morning, and thank you for having us. I'm joined today by our Chief Financial Officer, Brian Hahn, and we will be presenting the fiscal year 2024 preliminary results for AVACTA Therapeutics. Let's jump in. We will be making forward-looking statements, and our disclaimer is noted here on the second slide. Let me start with a few of the highlights for AVACTA. The company has essentially, over the last year, undergone a complete transformation, and we are now positioned as a pure play oncology biopharmaceutical company. When we joined you last year, this was a joined-up diagnostics and therapeutics company, and over the course of this last year, with the divestment of one of the aspects of the diagnostics company with the second one coming. We are now focused on our proprietary precision peptide drug conjugate platform within the company and are poised to move this into the next stage. Let me tell you a little bit about that and how we are accomplishing that. Our first entry into the clinic and really The program that created all the buzz and all the excitement around precision i...